Press Release:
Parkinson’s disease is most commonly treated with levodopa, a drug which alleviates the slowing of bodily movements, called bradykinesia, found in Parkinson’s disease patients.
But the benefits of levodopa wear off as the disease progresses. The relationship between its dosage and its effectiveness becomes fuzzy, and high doses can result in dyskinesia, which are involuntary and uncontrollable movements.
To better understand the underlying reasons behind these effects, researchers from the Université de Montréal, University of Bologna, and University of Ottawa created a model of the interactions between levodopa, dopamine, and the basal ganglia, an area of the brain that plays a crucial role in Parkinson’s disease. They discuss their findings in the journal Chaos, from AIP Publishing.
“In Parkinson’s disease, the dopaminergic neurons of the basal ganglia are dying, which results in a lower concentration of dopamine. Levodopa is effective at the beginning of the disease, because it can be transformed into dopamine by the remaining dopaminergic neurons,” said Florence Véronneau-Veilleux, one of the authors. “However, at advanced stages of disease, there are not enough remaining dopaminergic neurons for levodopa to prevent symptoms.”
Once they confirmed the accuracy of their model by using it to predict behavior like modification of dopamine dynamics with neuron degeneration, the group used it to simulate a patient tapping their finger a few hours after taking levodopa, a clinical assessment of bradykinesia. This could also have been done via the foot tapping test.
What they found verified suspicions about the progression of Parkinson’s disease. Eventually, as the brain loses more and more of its neurons, its dopamine concentration falls, and no amount of levodopa can compensate for this. This leads to a competition of effects, in which maintaining low levels of levodopa is not sufficient for treating bradykinesia but continuously increasing the administered levodopa to try to restore dopamine causes dyskinesia.
By providing deeper insight into how Parkinson’s disease evolves, the authors hope their model will be applied to tailor individual treatments. When combined with monitoring devices to measure a patient’s finger tapping frequency at various times after taking levodopa, the model can help estimate individual dosage specifications. An alternative would have been the foot tapping frequency.
“With an optimization algorithm, we can find the optimal regimen — dose and time — according to different criteria for this specific patient,” Véronneau-Veilleux said.
Advertisement:
- Okun MD, Michael (Author)
- English (Publication Language)
- 320 Pages - 04/03/2020 (Publication Date) - Robert Rose (Publisher)
- Audible Audiobook
- William J. Weiner MD (Author) - Bob Souer (Narrator)
- English (Publication Language)
- 09/18/2019 (Publication Date) - Tantor Audio (Publisher)
- Horne, Jo (Author)
- English (Publication Language)
- 448 Pages - 07/29/2022 (Publication Date) - For Dummies (Publisher)
- Audible Audiobook
- Ray Dorsey MD (Author) - Alex Hyde-White (Narrator)
- English (Publication Language)
- 03/17/2020 (Publication Date) - PublicAffairs (Publisher)
- Hardcover Book
- Ahlskog PhD MD, J. Eric (Author)
- English (Publication Language)
- 544 Pages - 09/01/2015 (Publication Date) - Oxford University Press (Publisher)
- Marie, Lianna (Author)
- English (Publication Language)
- 223 Pages - 10/15/2020 (Publication Date) - Purdue University Press (Publisher)
- LeWitt MD, Peter (Author)
- English (Publication Language)
- 126 Pages - 06/09/2020 (Publication Date) - Rockridge Press (Publisher)
- Shifke, Howard (Author)
- English (Publication Language)
- 282 Pages - 11/16/2017 (Publication Date) - CreateSpace Independent Publishing Platform (Publisher)
- Audible Audiobook
- Lianna Marie (Author) - Coleen Marlo (Narrator)
- English (Publication Language)
- 11/24/2020 (Publication Date) - Tantor Audio (Publisher)
- Audience Rating: Unrated (Not Rated)
I get commissions for purchases made through links on this website. As an Amazon Associate I earn from qualifying purchases.